Cigna Group Targets $45 EPS by 2030 as Specialty Growth Offsets Pharmacy Headwinds

Cigna Group (CI) aims for $45 EPS by 2030, with specialty growth offsetting pharmacy challenges. The company expects $20B revenue growth from CuraScript by 2030. Cigna plans a 40% debt-to-capital ratio by 2026, enabling share buybacks and acquisitions. Medical cost trends align with expectations, with elevated but stable costs anticipated.

Original reporting
Published Nov 11, 2026, 7:14 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 11, 2026, 7:22 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Cigna Group Targets $45 EPS by 2030 as Specialty Growth Offsets Pharmacy Headwinds — source image
Decision brief

The 30-second read

$CIBullishMed
01

Why it matters

The new EPS and revenue targets may drive a re‑rating of the stock's valuation multiples.

02

Market read

Guidance update is a primary corporate disclosure for a large‑cap insurer, offering a fresh data point for valuation models.

03

What to watch

Potential regulatory changes to specialty pharmacy reimbursements could temper growth.

Relevance 7/10Novelty 8/10Timing: today

Background

Cigna's Accelerate to One program aims for $3B in savings and expands CuraScript specialty pharmacy revenue.

Company-level read

Ticker impact

$CIBullishHigh confidence
Context

Cigna disclosed new EPS target of $45 by 2030 and $25B CuraScript revenue goal, a fresh guidance update.

Expected impact

likely upward pressure as investors price in stronger long‑term earnings outlook

Evidence & confidence

The $45 EPS target and $20B revenue add‑on are new, material numbers for a large‑cap insurer, prompting re‑valuation.

Market effects

May boost health‑insurance sector sentiment as Cigna signals strong specialty pharmacy growth.

U.S. market focus; limited direct regional effect.

Limited to investors tracking U.S. health‑care insurers.

Counterpoint

Guidance could be overly optimistic given rising drug costs and competitive pressures.

Key entities

  • Cigna Group

    Global health services insurer (ticker CI).

Related articles

$UNHMed

UnitedHealth and other insurance stocks drag down the Dow after CMS proposes new anti-fraud rule

UnitedHealth (UNH), Humana (HUM), Cigna (CI), and CVS Health (CVS) stocks fell 8%, 8%, 2%, and 3% respectively, dragging down the Dow after CMS proposed a new anti-fraud rule. The rule, called CRUSH, aims to increase audits and recover improper payments, potentially saving $90B over 10 years. Oppenheimer analysts expect legal challenges and note savings may not be broad.

$UNHHighAI 8/10

Positive Medicaid signals, open enrollment trends: Recapping major payers' Q3 results

UnitedHealth Group reported Q3 profit of $4.1B (up from $2.3B YoY) and revenue of $112.7B. CVS Health earned $2.2B (up from a $4B loss YoY) on $108.4B revenue, announcing a split of its pharmacy business. Cigna and Elevance Health each posted $1.4B profit. Centene reduced losses to $71M (from $6.6B YoY) on $50.6B revenue. Humana saw $162M profit (down from $195M) on $41.15B revenue, with positive Medicare enrollment trends.

$CIHighAI 8/10

What Cigna Group (CI) Said on Its Q3 Earnings Call

Cigna Group (CI) reported Q3 2026 adjusted revenue of $73.8B and adjusted earnings of $2.1B, raising its full-year EPS outlook to at least $30.60. Cigna Healthcare saw 9% revenue growth, while Evernorth's revenue rose 6%. The company expects 10% EPS growth in 2027, with cost savings targeting $3B by 2030.